NASDAQ: CYPHCypherpunk Technologies Inc Stock
$2.05+1.61 (+365.91%)
Updated Nov 12, 2025
CYPH Price
$2.05
Fair Value Price
$1.25
Market Cap
$116.14M
52 Week Low
$0.22
52 Week High
$3.58
P/E
-1.68x
P/B
43.09x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$50.81M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
3.23
Operating Cash Flow
-$53M
Beta
1.41
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
CYPH Overview
Cypherpunk Technologies Inc., a biopharmaceutical company, acquires and develops antibody therapies for the treatment of cancer. Its lead clinical stage drug candidate includes DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in various ongoing clinical trials for treating esophagogastric and gynecologic cancers, and colorectal cancer. The company also develops FL-501, a monoclonal antibody that inhibits GDF-15 protein that is in preclinical trial. It has an option and license agreement with Adimab, LLC and BeiGene, Ltd. to develop and commercialize DKN-01 in Asia (excluding Japan), Australia, and New Zealand. The company was formerly known as Leap Therapeutics, Inc. and changed its name to Cypherpunk Technologies Inc. in November 2025. The company was incorporated in 2011 and is based in Cambridge, Massachusetts.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine CYPH's potential to beat the market
- CYPH doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Be the first to know about important CYPH news, forecast changes, insider trades & much more!
CYPH News
Overview
Due Diligence Score
–
Industry Average (23)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how CYPH scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
CYPH ($2.05) is overvalued by 63.84% relative to our estimate of its Fair Value price of $1.25 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
CYPH ($2.05) is not significantly undervalued (63.84%) relative to our estimate of its Fair Value price of $1.25 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
CYPH is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more CYPH due diligence checks available for Premium users.
Valuation
CYPH fair value
Fair Value of CYPH stock based on Discounted Cash Flow (DCF)
Price
$2.05
Fair Value
$1.25
Overvalued by
63.84%
CYPH ($2.05) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
CYPH ($2.05) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
CYPH is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
CYPH price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-1.68x
Industry
281.87x
Market
44.84x
CYPH price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
43.09x
Industry
5.09x
CYPH is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
CYPH's financial health
Profit margin
Revenue
$0.0
Net Income
-$3.3M
Profit Margin
0%
CYPH's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$11.4M
Liabilities
$8.7M
Debt to equity
3.23
CYPH's short-term assets ($10.50M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
CYPH's short-term assets ($10.50M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
CYPH's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
CYPH's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$8.3M
Investing
$0.0
Financing
-$121.0k
CYPH's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
CYPH vs Biotech Stocks
Cypherpunk Technologies Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.